{"id":"bacteriophage-treatment","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Bacteriophages are viruses that target bacterial cells, causing them to lyse and die. This mechanism is particularly useful in treating bacterial infections that are resistant to traditional antibiotics.","oneSentence":"Bacteriophages selectively infect and kill bacteria","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:22:03.621Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial infections"}]},"trialDetails":[{"nctId":"NCT07492771","phase":"PHASE1","title":"MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia","status":"NOT_YET_RECRUITING","sponsor":"MicrobiotiX Co., Ltd","startDate":"2026-03","conditions":"Pneumonia - Bacterial, Pseudomonas Aeruginosa Infection","enrollment":18},{"nctId":"NCT05184764","phase":"PHASE1, PHASE2","title":"Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia","status":"COMPLETED","sponsor":"Armata Pharmaceuticals, Inc.","startDate":"2022-04-26","conditions":"Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia","enrollment":56},{"nctId":"NCT05488340","phase":"PHASE2","title":"A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)","status":"RECRUITING","sponsor":"Locus Biosciences","startDate":"2022-07-13","conditions":"Urinary Tract Infections","enrollment":318},{"nctId":"NCT02664740","phase":"PHASE1, PHASE2","title":"Standard Treatment Associated With Phage Therapy Versus Placebo for Diabetic Foot Ulcers Infected by S. Aureus","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2026-09-01","conditions":"Diabetic Foot, Staphylococcal Infections","enrollment":60},{"nctId":"NCT06870409","phase":"PHASE3","title":"Bacteriophages in Addition to Antibiotics for the Treatment of Patients With Infective Endocarditis","status":"RECRUITING","sponsor":"University Clinical Hospital na V.V.Vinogradov (branch of RUDN university na Patrice Lumumba)","startDate":"2025-02-05","conditions":"Endocarditis, Bacterial","enrollment":30},{"nctId":"NCT07461337","phase":"PHASE1, PHASE2","title":"Bacteriophage Therapy for Staphylococcus Lugdunensis Prosthetic Joint Infection","status":"NOT_YET_RECRUITING","sponsor":"University of Calgary","startDate":"2026-03","conditions":"Prosthetic Joint Infections of Hip, Bacteriophage Therapy","enrollment":1},{"nctId":"NCT07429162","phase":"PHASE1","title":"Bacteriophage for Chronic Multidrug-Resistant Mycobacterium Abscessus Subsp. Abscessus Pulmonary Infection","status":"NOT_YET_RECRUITING","sponsor":"Alberta Health services","startDate":"2026-07-02","conditions":"Mycobacterium Abscessus Infection, Bacteriophage Therapy, Pulmonary Disease","enrollment":1},{"nctId":"NCT07275905","phase":"PHASE1","title":"Bacteriophages for Adults With Cystic Fibrosis and Chronic Achromobacter Lung Infection","status":"NOT_YET_RECRUITING","sponsor":"Ghady Haidar","startDate":"2026-03","conditions":"Cystic Fibrosis (CF), Achromobacter Infection","enrollment":12},{"nctId":"NCT07382271","phase":"NA","title":"Evaluation of Safety and Efficacy of Phage Therapy for Drug-resistant Bacterial Infections: An Exploratory, Prospective Single-arm Study","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2026-02","conditions":"Urinary Tract Infections, Urinary Tract Infections Caused by Drug-resistant Bacteria","enrollment":6},{"nctId":"NCT07338123","phase":"EARLY_PHASE1","title":"A Randomized Controlled Trial (RCT) of Yiqi Huoxue Jiedu Formula Combined With Bacteriophages in the Treatment of Severe Pneumonia Caused by Drug-resistant Gram-negative Bacilli","status":"NOT_YET_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2026-02-01","conditions":"Pneumonia","enrollment":240},{"nctId":"NCT05616221","phase":"PHASE2","title":"Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection","status":"COMPLETED","sponsor":"Armata Pharmaceuticals, Inc.","startDate":"2023-01-10","conditions":"Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection","enrollment":48},{"nctId":"NCT05948592","phase":"PHASE2","title":"Bacteriophage Therapy TP-102 in Patients With Diabetic Foot Infection","status":"COMPLETED","sponsor":"Technophage, SA","startDate":"2023-11-08","conditions":"Diabetic Foot Infection","enrollment":76},{"nctId":"NCT05453578","phase":"PHASE1, PHASE2","title":"A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-10-03","conditions":"Bacterial Disease Carrier, Cystic Fibrosis","enrollment":72},{"nctId":"NCT07280598","phase":"PHASE1","title":"Safety of Combined Intravenous Antibiotic and Bacteriophage Therapy in Adults With Cystic Fibrosis and Antibiotic-Resistant Lung Infections","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Diego","startDate":"2025-12-31","conditions":"CF - Cystic Fibrosis, Klebsiella Pneumoniae Infection, E Coli Infections","enrollment":30},{"nctId":"NCT07240181","phase":"","title":"OPTImization of Inflammatory Bowel Disease Treatment Through Understanding of Gut VIRome Heterogeneity","status":"NOT_YET_RECRUITING","sponsor":"Andreas Munk Petersen","startDate":"2025-12-01","conditions":"IBD (Inflammatory Bowel Disease), Crohns Disease, Colitis Ulcerative","enrollment":40},{"nctId":"NCT07228702","phase":"PHASE1","title":"Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection","status":"ENROLLING_BY_INVITATION","sponsor":"Vancouver Coastal Health","startDate":"2025-11","conditions":"Non-Tuberculous Mycobacterial (NTM) Pneumonia, Mycobacterium Abscessus Infection","enrollment":1},{"nctId":"NCT06834984","phase":"NA","title":"Ritual Synbiotic+, a Dietary Supplement Designed to Impact Gastrointestinal Health, Mood, and Behavior in Women","status":"RECRUITING","sponsor":"Colorado State University","startDate":"2025-05-01","conditions":"Gastrointestinal Disease Symptoms","enrollment":60},{"nctId":"NCT07076238","phase":"","title":"Biomarkers of Phage Treatment Response in NTM and Other Infections","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-06-25","conditions":"Nontuberculous Mycobacterial Lung Disease","enrollment":100},{"nctId":"NCT06938867","phase":"PHASE1, PHASE2","title":"Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant","status":"RECRUITING","sponsor":"SNIPR Biome Aps.","startDate":"2025-02-25","conditions":"E Coli Infections, Allogenic Transplant Patients","enrollment":24},{"nctId":"NCT07202234","phase":"NA","title":"Bacteriophage Cocktail Therapy for Multidrug-Resistant Gram-Negative Ventilator-Associated Pneumonia","status":"NOT_YET_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-11-01","conditions":"VAP - Ventilator Associated Pneumonia","enrollment":248},{"nctId":"NCT05177107","phase":"PHASE2","title":"Bacteriophage Therapy in Patients With Diabetic Foot Osteomyelitis","status":"TERMINATED","sponsor":"Adaptive Phage Therapeutics, Inc.","startDate":"2021-11-24","conditions":"Osteomyelitis, Diabetic Foot Osteomyelitis","enrollment":41},{"nctId":"NCT06750588","phase":"PHASE1","title":"Safety and Tolerability of NTR-101 in Patients With Acute Alcohol-Associated Hepatitis","status":"NOT_YET_RECRUITING","sponsor":"Nterica Bio inc","startDate":"2025-11-05","conditions":"Alcohol-Associated Hepatitis","enrollment":12},{"nctId":"NCT06409819","phase":"PHASE1, PHASE2","title":"Phage Therapy for Recurrent UTIs in Kidney Transplant Recipients","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2025-06-15","conditions":"Urinary Tract Infection, Recurrent","enrollment":32},{"nctId":"NCT06998043","phase":"PHASE2","title":"Study With Phage for CF Subjects With Pseudomonas Lung Infection","status":"RECRUITING","sponsor":"BiomX Ltd","startDate":"2025-07-02","conditions":"Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis (CF)","enrollment":63},{"nctId":"NCT05010577","phase":"PHASE1, PHASE2","title":"Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection","status":"COMPLETED","sponsor":"BiomX, Inc.","startDate":"2022-06-21","conditions":"Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis","enrollment":43},{"nctId":"NCT06070428","phase":"NA","title":"Project 4: ACHIEVE PATHFINDER","status":"RECRUITING","sponsor":"Henry Ford Health System","startDate":"2023-12-18","conditions":"Heart Failure","enrollment":400},{"nctId":"NCT05182749","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Intralytix, Inc.","startDate":"2023-02-23","conditions":"Shigellosis","enrollment":52},{"nctId":"NCT03808103","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Intralytix, Inc.","startDate":"2019-05-01","conditions":"Crohn Disease","enrollment":30},{"nctId":"NCT06814756","phase":"PHASE1, PHASE2","title":"Bacteriophage Therapy for Morganella Morganii Prosthetic Joint Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Calgary","startDate":"2025-03-26","conditions":"Prosthetic Joint Infections of Hip","enrollment":1},{"nctId":"NCT06456424","phase":"PHASE1, PHASE2","title":"Bacteriophage Therapy for Methicillin-Sensitive Staphylococcus Aureus Prosthetic Joint Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Calgary","startDate":"2024-11-20","conditions":"Prosthetic Joint Infections of Hip, Staphylococcus Aureus Infection","enrollment":1},{"nctId":"NCT05967130","phase":"PHASE3","title":"Treatment Chronic UTI Post Kidney Transplant","status":"TERMINATED","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2023-07-01","conditions":"Urinary Tract Infections, Transplant-Related Disorder","enrollment":5},{"nctId":"NCT06262282","phase":"","title":"Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria","status":"ENROLLING_BY_INVITATION","sponsor":"National Jewish Health","startDate":"2024-02-05","conditions":"Cystic Fibrosis, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterium Infection","enrollment":10},{"nctId":"NCT04682964","phase":"PHASE3","title":"Bacteriophage Therapy in Tonsillitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tashkent State Medical University (Tashkent Pediatric Medical Institute), Uzbekistan","startDate":"2020-10-02","conditions":"Acute Tonsillitis","enrollment":128},{"nctId":"NCT06559618","phase":"PHASE1","title":"Bacteriophage Therapy in Spinal Cord Injury Patients With Bacteriuria","status":"RECRUITING","sponsor":"Barbara Wells Trautner","startDate":"2025-02-03","conditions":"Bacteriuria, Spinal Cord Injuries, Asymptomatic Bacteriuria","enrollment":30},{"nctId":"NCT06942624","phase":"PHASE1, PHASE2","title":"Phage Therapy for the Treatment of a Chronic Enterococcus Faecium Periprosthetic Joint Infection","status":"NOT_YET_RECRUITING","sponsor":"Orthopaedic Innovation Centre","startDate":"2025-05","conditions":"Periprosthetic Joint Infection","enrollment":1},{"nctId":"NCT06827041","phase":"PHASE1","title":"Use of Phage Therapy for Treatment of a Periprosthetic Joint Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2024-02-22","conditions":"Periprosthetic Joint Infection","enrollment":1},{"nctId":"NCT06798168","phase":"","title":"Bacteriophage Clinical Trial for Periprosthetic Joint Infection of Multidrug Resistant Pseudomonas Aeruginosa","status":"AVAILABLE","sponsor":"Ottawa Hospital Research Institute","startDate":"","conditions":"Joint Infection","enrollment":""},{"nctId":"NCT05272579","phase":"EARLY_PHASE1","title":"PrePhage - Faecal Bacteriophage Transfer for Enhanced Gastrointestinal Tract Maturation in Preterm Infants","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2023-11-07","conditions":"Necrotizing Enterocolitis, Microbial Substitution","enrollment":20},{"nctId":"NCT05457140","phase":"NA","title":"Multiomic Diagnostics in Youth With Psychosis","status":"RECRUITING","sponsor":"Rady Pediatric Genomics & Systems Medicine Institute","startDate":"2022-10-10","conditions":"Psychosis","enrollment":15},{"nctId":"NCT06656572","phase":"NA","title":"Immunogenomic Analyses of Pediatric Catatonia","status":"NOT_YET_RECRUITING","sponsor":"Rady Pediatric Genomics & Systems Medicine Institute","startDate":"2024-12-01","conditions":"Catatonia","enrollment":120},{"nctId":"NCT06605651","phase":"PHASE2","title":"Proof of Concept Study to Assess Safety and Efficacy of Phage Therapy in Hip or Knee Prosthetic Joint Infections Due to Staphylococcus Aureus Treated by DAIR.","status":"NOT_YET_RECRUITING","sponsor":"Phaxiam Therapeutics","startDate":"2025-01","conditions":"Hip Prosthesis Infection, Knee Prosthesis Infection","enrollment":100},{"nctId":"NCT06370598","phase":"PHASE1, PHASE2","title":"Phase 1/2a to Assess the Safety and Tolerability of TP-122A for the Treatment of Ventilator-Associated Pneumonia","status":"NOT_YET_RECRUITING","sponsor":"Technophage, SA","startDate":"2024-09","conditions":"Pneumonia, Ventilator-Associated","enrollment":15},{"nctId":"NCT06368388","phase":"","title":"Bacteriophage Therapy for Difficult-to-treat Infections: the Implementation of a Multidisciplinary Phage Task Force","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2021-06-01","conditions":"Musculoskeletal Infection, Chronic Rhinosinusitis (Diagnosis), Sepsis","enrollment":50},{"nctId":"NCT05537519","phase":"PHASE1, PHASE2","title":"Phage Therapy for the Treatment of Urinary Tract Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Unity Health Toronto","startDate":"2023-05-01","conditions":"Recurrent Urinary Tract Infection","enrollment":1},{"nctId":"NCT06319235","phase":"PHASE1, PHASE2","title":"Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®","status":"RECRUITING","sponsor":"MB PHARMA s.r.o.","startDate":"2023-10-27","conditions":"Surgical Site Infection, Staphylococcus Aureus Infection, Pseudomonas Aeruginosa Infection","enrollment":52},{"nctId":"NCT05269121","phase":"PHASE1, PHASE2","title":"Bacteriophage Therapy in First Time Chronic Prosthetic Joint Infections","status":"WITHDRAWN","sponsor":"Adaptive Phage Therapeutics, Inc.","startDate":"2022-09","conditions":"Prosthetic Joint Infection, Bacterial Infections","enrollment":""},{"nctId":"NCT04596319","phase":"PHASE1, PHASE2","title":"Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis","status":"COMPLETED","sponsor":"Armata Pharmaceuticals, Inc.","startDate":"2020-12-22","conditions":"Cystic Fibrosis, Pseudomonas Aeruginosa, Pseudomonas","enrollment":29},{"nctId":"NCT05590195","phase":"PHASE3","title":"Effect of PreforPro® on Urinary and Vaginal Health","status":"UNKNOWN","sponsor":"Jeremy Burton","startDate":"2024-05-01","conditions":"Bacterial Vaginosis, Bacterial Infections, Bacterial Vaginosis | Vaginal | Microbiology","enrollment":50},{"nctId":"NCT06185920","phase":"","title":"PHAGEinLYON Clinic Cohort Study: a Descriptive Study of Severe Infections Treated With Phage Therapy at the HCL.","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2023-02-01","conditions":"Severe Infection","enrollment":250},{"nctId":"NCT03835520","phase":"NA","title":"Prospective Collection of Tumor Biopsy and Plasma Samples From Cancer Patients Treated With Molecular Targeted Therapies or Immunotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2018-07-11","conditions":"Cancer","enrollment":200},{"nctId":"NCT05269134","phase":"PHASE2","title":"Bacteriophage Therapy in Patients With Prosthetic Joint Infections (PJI)","status":"WITHDRAWN","sponsor":"Adaptive Phage Therapeutics, Inc.","startDate":"2023-03-27","conditions":"Prosthetic Joint Infection","enrollment":""},{"nctId":"NCT04684641","phase":"PHASE1, PHASE2","title":"CYstic Fibrosis bacterioPHage Study at Yale (CYPHY)","status":"COMPLETED","sponsor":"Yale University","startDate":"2021-03-29","conditions":"Cystic Fibrosis","enrollment":8},{"nctId":"NCT05715619","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Oral Administration of the Phage Cocktail, VRELysin™, In Healthy and VRE-Colonized Subjects","status":"UNKNOWN","sponsor":"Intralytix, Inc.","startDate":"2023-10-25","conditions":"Vancomycin-Resistant Enterococcal Colonization","enrollment":80},{"nctId":"NCT05973721","phase":"NA","title":"Clinical Study of Phage Therapy for Chronic Constipation Efficacy and Safety","status":"UNKNOWN","sponsor":"Shanghai 10th People's Hospital","startDate":"2023-07-01","conditions":"Pib Specific Phage, Intractable Constipation","enrollment":50},{"nctId":"NCT05883995","phase":"","title":"Avis-PHAGEinLYON Clinic","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2023-02-01","conditions":"Bone Infection","enrollment":1500},{"nctId":"NCT04650607","phase":"","title":"Phage Safety Cohort Study","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2022-05-09","conditions":"Prosthetic Joint Infection, Severe Infection","enrollment":100},{"nctId":"NCT04287478","phase":"PHASE1, PHASE2","title":"Bacteriophage Therapy in Patients With Urinary Tract Infections","status":"TERMINATED","sponsor":"Adaptive Phage Therapeutics, Inc.","startDate":"2020-12-09","conditions":"Urinary Tract Infection Bacterial","enrollment":1},{"nctId":"NCT05618418","phase":"","title":"BActeriophages To Treat Liver Disease Eliminating Harmful Bacteria (BATTLE)","status":"UNKNOWN","sponsor":"Copenhagen University Hospital, Hvidovre","startDate":"2022-07-01","conditions":"Alcoholic Hepatitis","enrollment":30},{"nctId":"NCT04708704","phase":"NA","title":"Photodegraded Edible Food Dyes","status":"WITHDRAWN","sponsor":"Yale University","startDate":"2022-09-01","conditions":"Thyroid; Functional Disturbance","enrollment":""},{"nctId":"NCT04803708","phase":"PHASE1, PHASE2","title":"Bacteriophage Therapy TP-102 in Diabetic Foot Ulcers","status":"COMPLETED","sponsor":"Technophage, SA","startDate":"2021-03-22","conditions":"Diabetic Foot Ulcer, Pseudomonas Aeruginosa Infection, Staphylococcus Aureus Infection","enrollment":20},{"nctId":"NCT05498363","phase":"","title":"Bacteriophage Therapy of Difficult-to-treat Infections","status":"COMPLETED","sponsor":"Queen Astrid Military Hospital","startDate":"2008-01-01","conditions":"Bacterial Infections","enrollment":100},{"nctId":"NCT05369104","phase":"PHASE2","title":"Phage Therapy in Prosthetic Joint Infection Due to Staphylococcus Aureus Treated With DAIR.","status":"UNKNOWN","sponsor":"Phaxiam Therapeutics","startDate":"2022-06-15","conditions":"Infection of Total Hip Joint Prosthesis, Infection of Total Knee Joint Prosthesis","enrollment":64},{"nctId":"NCT04787250","phase":"PHASE1, PHASE2","title":"Bacteriophage Therapy in Patients With Prosthetic Joint Infections","status":"WITHDRAWN","sponsor":"Adaptive Phage Therapeutics, Inc.","startDate":"2022-10","conditions":"Prosthetic Joint Infection","enrollment":""},{"nctId":"NCT04191148","phase":"PHASE1","title":"Safety, Tolerability, and PK of LBP-EC01 in Patients With Lower Urinary Tract Colonization Caused by E. Coli","status":"COMPLETED","sponsor":"Locus Biosciences","startDate":"2019-12-30","conditions":"Urinary Tract Infections","enrollment":36},{"nctId":"NCT04737876","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, and Fecal Pharmacokinetics of BX002-A in Healthy Adults","status":"COMPLETED","sponsor":"BiomX, Inc.","startDate":"2020-10-28","conditions":"Healthy Volunteers","enrollment":18},{"nctId":"NCT04323475","phase":"PHASE1","title":"Phage Therapy for the Prevention and Treatment of Wound Infections in Burned Patients","status":"UNKNOWN","sponsor":"Precisio Biotix Therapeutics, Inc.","startDate":"2022-01","conditions":"Wound Infection","enrollment":12},{"nctId":"NCT04636554","phase":"","title":"Personalized Phage Treatment in Covid-19 Patients With Bacterial Co-Infections Microbials for Pneumonia or Bacteremia/Septicemia","status":"NO_LONGER_AVAILABLE","sponsor":"Adaptive Phage Therapeutics, Inc.","startDate":"","conditions":"Covid19, Bacteremia, Septicemia","enrollment":""},{"nctId":"NCT04815798","phase":"PHASE1, PHASE2","title":"Phage Therapy for the Prevention and Treatment of Pressure Ulcers.","status":"UNKNOWN","sponsor":"Precisio Biotix Therapeutics, Inc.","startDate":"2022-01","conditions":"Pressure Ulcer","enrollment":69},{"nctId":"NCT00006066","phase":"PHASE1","title":"Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":92},{"nctId":"NCT02957370","phase":"","title":"Molecular Biosensors for Detection of Bladder Cancer","status":"UNKNOWN","sponsor":"University of California, Irvine","startDate":"2015-06-11","conditions":"Urinary Bladder Neoplasms","enrollment":230},{"nctId":"NCT00677495","phase":"NA","title":"Gluten-free Diet in Gluten-genetically Predisposed Subjects","status":"COMPLETED","sponsor":"IRCCS Burlo Garofolo","startDate":"2007-05","conditions":"Genetic Predisposition to Disease, Celiac Disease","enrollment":30},{"nctId":"NCT03395769","phase":"","title":"Individual Patient Expanded Access for AB-SA01, an Investigational Anti-Staphylococcus Aureus Bacteriophage Therapeutic","status":"NO_LONGER_AVAILABLE","sponsor":"Armata Pharmaceuticals, Inc.","startDate":"","conditions":"","enrollment":""},{"nctId":"NCT03395743","phase":"","title":"Individual Patient Expanded Access for AB-PA01, an Investigational Anti-Pseudomonas Aeruginosa Bacteriophage Therapeutic","status":"NO_LONGER_AVAILABLE","sponsor":"Armata Pharmaceuticals, Inc.","startDate":"","conditions":"","enrollment":""},{"nctId":"NCT03140085","phase":"PHASE2, PHASE3","title":"Bacteriophages for Treating Urinary Tract Infections in Patients Undergoing Transurethral Resection of the Prostate","status":"COMPLETED","sponsor":"Balgrist University Hospital","startDate":"2017-06-02","conditions":"Intravesical Bacteriophage Treatment for Urinary Tract Infections","enrollment":97},{"nctId":"NCT02116010","phase":"PHASE1, PHASE2","title":"Evaluation of Phage Therapy for the Treatment of Escherichia Coli and Pseudomonas Aeruginosa Wound Infections in Burned Patients","status":"UNKNOWN","sponsor":"Phaxiam Therapeutics","startDate":"2015-07","conditions":"Wound Infection","enrollment":""},{"nctId":"NCT00785967","phase":"PHASE3","title":"Immune Responses in Patients Treated With Raltegravir","status":"WITHDRAWN","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2009-01","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00937274","phase":"NA","title":"Antibacterial Treatment Against Diarrhea in Oral Rehydration Solution","status":"TERMINATED","sponsor":"Société des Produits Nestlé (SPN)","startDate":"2009-08","conditions":"Diarrhea","enrollment":120},{"nctId":"NCT00945087","phase":"NA","title":"Experimental Phage Therapy of Bacterial Infections","status":"UNKNOWN","sponsor":"Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences","startDate":"2005-12","conditions":"Bacterial Infections","enrollment":""},{"nctId":"NCT00663091","phase":"PHASE1","title":"A Prospective, Randomized, Double-Blind Controlled Study of WPP-201 for the Safety and Efficacy of Treatment of Venous Leg Ulcers","status":"COMPLETED","sponsor":"Southwest Regional Wound Care Center","startDate":"2006-09","conditions":"Venous Leg Ulcers","enrollment":64}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":142,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Bacteriophage Treatment","genericName":"Bacteriophage Treatment","companyName":"NYU Langone Health","companyId":"nyu-langone-health","modality":"Biologic","firstApprovalDate":"","aiSummary":"Bacteriophages selectively infect and kill bacteria Used for Bacterial infections.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}